Exploratory Assessment of Galectin-1, -3, and -9 in Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Biochemistry

Background:

• Galectins are key in lung cancer development, affecting cell death, blood vessel growth, and spread.
• Biomarkers are vital for diagnosing, predicting outcomes, and guiding treatment for non-small cell lung cancer (NSCLC).
• Galectins show promise as biomarkers for NSCLC.

Purpose of the Study:

• To investigate serum galectin-1, -3, and -9 levels in NSCLC patients.
• To explore the association between galectin levels and clinical factors, including cancer type, stage, treatment, and patient outcomes.
• To assess the prognostic value of galectins in NSCLC.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to measure serum galectin levels.
• Retrospective chart review analyzed patient demographics, cancer characteristics, and outcomes.
• Statistical comparisons were made between galectin levels and various clinical parameters.

Main Results:

• Galectin-3 levels were significantly lower in squamous cell lung cancer and in patients who received chemotherapy.
• Galectin-1 levels were lower in patients with prior metastasis but did not predict future metastasis.
• Abnormal galectin-1 levels correlated with reduced overall survival (OS) in NSCLC, particularly in surgically resectable cases, though not in multivariable analysis.

Conclusions:

• Galectin-3 levels may serve as a biomarker in specific NSCLC subtypes or treatment contexts.
• Galectin-1 shows potential as a prognostic marker for surgically resectable NSCLC.
• These findings support further research into galectins as therapeutic targets and prognostic indicators in lung cancer.